Heron Therapeutics Inc (NASDAQ:HRTX) shares, rose in value, without any change to the previous day’s close as strong demand from buyers drove the stock to $2.57.
Actively observing the price movement in the last trading, the stock closed the session at $2.57. The value of beta (5-year monthly) was 1.71. Referring to stock’s 52-week performance, its high was $3.22, and the low was $0.50. On the whole, HRTX has fluctuated by 0.39% over the past month.
With the market capitalization of Heron Therapeutics Inc currently standing at about $386.35 million, investors are eagerly awaiting this quarter’s results, scheduled for May 09, 2024 – May 13, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.09, which is expected to increase to -$0.05 for fiscal year -$0.45 and then to about -$0.36 by fiscal year 2025. Data indicates that the EPS growth is expected to be 43.80% in 2025, while the next year’s EPS growth is forecast to be 20.00%.
Analysts have estimated the company’s revenue for the quarter at $32.8 million, with a low estimate of $30.9 million and a high estimate of $34.4 million. According to the average forecast, sales growth in current quarter could jump up 10.80%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $145.93 million, representing an increase of 14.90% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that HRTX’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of HRTX currently trading nearly -7.50% and -2.83% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 42.95, while the 7-day volatility ratio is showing 5.34% which for the 30-day chart, stands at 8.12%. Furthermore, Heron Therapeutics Inc (HRTX)’s beta value is 1.72, and its average true range (ATR) is 0.20.
A comparison of Heron Therapeutics Inc (HRTX) with its peers suggests the former has fared considerably weaker in the market. HRTX showed an intraday change of 0.00% in last session, and over the past year, it grew by 44.38%%.
Data on historical trading for Heron Therapeutics Inc (NASDAQ:HRTX) indicates that the trading volumes over the past 10 days have averaged 1.44 million and over the past 3 months, they’ve averaged 2.99 million. According to company’s latest data on outstanding shares, there are 150.29 million shares outstanding.
Nearly 5.05% of Heron Therapeutics Inc’s shares belong to company insiders and institutional investors own 71.22% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 25.43 million shares as on Mar 15, 2024, resulting in a short ratio of 8.61. According to the data, the short interest in Heron Therapeutics Inc (HRTX) stood at 16.91% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 24.62 million. The stock has risen by 51.18% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the HRTX stock heading into the next quarter.
